In the landscape of modern drug discovery, a profound shift is underway. For decades, the pathology laboratory was a terminal point for scientific inquiry: a tissue sample was processed, a pathologist rendered a diagnosis, and the physical slide was filed away into long-term storage, effectively becoming “dead” data. Today, however, that paradigm is being inverted. Through the integration of high-resolution digital pathology, artificial intelligence (AI), and advanced molecular analysis, these archival vaults are being transformed into rich, living repositories of biological insight.
This digital evolution is not merely a technological upgrade; it is a fundamental driver of the pharmaceutical industry’s commitment to the "3Rs"—Replacement, Reduction, and Refinement—in animal research. By extracting more data from the animals already involved in studies, researchers are finding ways to circumvent the need for new, redundant experiments, aligning the industry with a regulatory future that increasingly favors non-animal methodologies (NAMs).
A Paradigm Shift: From Physical Slides to Pixels
The catalyst for this transformation was the COVID-19 pandemic. Faced with lockdowns and travel restrictions, the pathology field underwent a forced, rapid transition to digital workflows. What began as a necessity for remote diagnostic sign-out quickly revealed a deeper utility: when pathology is digitized, it becomes data.
“Before, the pathology endpoint was just a report,” explains Aleksandra Zuraw, DVM, PhD, a veterinary pathologist at Charles River Laboratories. “Now you have the digitized slide, which is pixels.”
Once converted to pixels, these images are no longer static snapshots. They can be analyzed by machine learning algorithms to identify subtle, non-linear patterns that the human eye might overlook. These patterns often correlate with complex molecular changes, allowing researchers to re-interrogate old studies to answer questions that were not even conceived when the original samples were first collected.
Chronology of a Digital Transformation
The path to this digital, data-centric model has evolved in distinct phases, largely dictated by the intersection of technological capability and regulatory necessity.
- 2020–2021 (The Pandemic Acceleration): Digital pathology moves from a niche tool to a standard operating procedure. The widespread adoption of slide scanners allows for the creation of massive, centralized digital libraries.
- 2022 (Legislative Milestone): The U.S. enacts the FDA Modernization Act 2.0, legally authorizing the use of non-animal testing methods for drug development applications. This sets a formal regulatory tone that innovation must prioritize alternatives.
- 2024 (Strategic Pivoting): Charles River Laboratories launches its "Alternative Methods Advancement Project," signaling a shift in industry giants toward formalizing these new methodologies.
- 2025–2026 (Regulatory Roadmap): The FDA publishes specific roadmaps for reducing animal testing, starting with biologics and monoclonal antibodies. Simultaneously, the OECD provides new guidance on leveraging stored tissue for molecular omics analysis, effectively legitimizing the use of historical samples.
Supporting Data: The Power of "Virtual" and "Archived" Methods
The drive to reduce animal usage is not just a moral imperative; it is a mathematical one. By optimizing the data yield per subject, researchers can significantly reduce the number of animals required for statistical significance.
The Rise of Virtual Control Groups
In traditional toxicology, a significant portion of animal subjects are relegated to the "control group." These animals receive no drug, serving only to establish a baseline of normal biological behavior against which the experimental group is measured.
Charles River is pioneering the use of "virtual control groups," where historical data from previous studies is used to replace the need for concurrent control animals. The challenge, of course, is validity: researchers must prove that the historical conditions are perfectly matched to the current study. When successfully implemented, the reduction in animal usage is immediate and substantial.
Unlocking FFPE Blocks
Toxicology studies rely heavily on Formalin-Fixed, Paraffin-Embedded (FFPE) tissue blocks. Historically, these blocks were considered the end-of-life for a sample. Today, they are viewed as high-value assets.
The OECD’s 2025 guidance acknowledges that preserved tissue—if properly stored—can yield valid data for gene expression and protein analysis. When a researcher realizes, post-study, that they need to understand the mechanism behind a specific toxicity finding, they no longer need to design a new, live-animal experiment. Instead, they can return to the archive, perform molecular assays on the stored blocks, and correlate those findings with the original dose data and pathology reports.
The Technological Frontier: Virtual Staining
Perhaps the most "cutting-edge" development in this field is the concept of virtual staining. Traditionally, a pathologist must apply chemical stains to a tissue section to visualize cell structures under a microscope.
Virtual staining removes this physical step. Software algorithms can analyze an unstained, digitized tissue section and generate the expected stained image. Beyond just saving time and materials, this technology allows for a single tissue section to be "stained" in multiple different ways—or even in ways that are impossible with traditional chemistry—by simply toggling different software filters. As this field matures, it promises a future where physical slide preparation is drastically minimized, if not entirely eliminated, for many research applications.
Official Responses and Regulatory Implications
The FDA’s stance has been clear and increasingly assertive. The roadmap released in April 2025 serves as a signal to the pharmaceutical industry that the era of "animal-first" testing is closing.
“The agency aims to make animal studies the exception rather than the norm,” the roadmap suggests, with new approach methodologies (NAMs) positioned as the new default. This regulatory pressure is forcing companies to move beyond pilot projects and integrate these methods into their core operational strategies.
However, Dr. Zuraw cautions that this transition requires more than just high-tech software; it requires a culture of "early adoption."
“You still need enough early adopters to generate precedent,” Zuraw notes. “Those early adopters will embrace the guidance, figure it out and troubleshoot, and then others can build on their work without reinventing the wheel.”
Implications for the Future of Drug Discovery
The implications of these developments are twofold: ethical and scientific.
Ethically, the industry is moving closer to the vision of a "no-animal" drug discovery pipeline. While we are not there yet, the ability to mine existing data instead of creating new life for experimentation is a massive step forward in reducing the ethical burden of preclinical research.
Scientifically, the move toward digital pathology is creating a "snowball effect." As more labs invest in scanning, storage, and AI-driven analysis, the industry is building a massive, interconnected network of biological intelligence. This allows for a deeper understanding of drug-tissue interactions. By treating digital slides as data points rather than physical artifacts, researchers can compare results across different labs, different drug classes, and different time periods, identifying subtle toxicity markers that were previously invisible.
Ultimately, the goal is to make the drug discovery process more efficient, more reliable, and more humane. As the "snowball" continues to roll, the legacy tissue that once sat dusty in storage boxes is being repurposed as the foundation for the next generation of life-saving medicines. The industry is proving that we do not always need more animals to get better answers—sometimes, we simply need better ways to look at the data we already possess.
About the Author
